(Q38114031)

29 August 2017

title

The Nrf2 pathway in the progression of renal disease (English)

1 reference

29 August 2017

3

1 reference

29 August 2017

Ariela Benigni

2

0 references

Carlamaria Zoja

series ordinal

1

object named as

Carlamaria Zoja

1 reference

29 August 2017

language of work or name

English

0 references

publication date

11 June 2013

1 reference

Nephrology Dialysis Transplantation

29 August 2017

published in

1 reference

29 August 2017

volume

29 Suppl 1

1 reference

29 August 2017

page(s)

i19-i24

1 reference

Nrf2-Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Nrf2-Keap1 defines a physiologically important stress response mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Hypoxia. 1. Intracellular sensors for oxygen and oxidative stress: novel therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Nrf2 signaling: an adaptive response pathway for protection against environmental toxic insults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Regulation of Nrf2 transactivation domain activity. The differential effects of mitogen-activated protein kinase cascades and synergistic stimulatory effect of Raf and CREB-binding protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

CCAAT enhancer-binding protein alpha suppresses the rat placental glutathione S-transferase gene in normal liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

p53 suppresses the Nrf2-dependent transcription of antioxidant response genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Nrf2, a multi-organ protector?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Nrf2-deficient female mice develop lupus-like autoimmune nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Transcription factor Nrf2 is protective during ischemic and nephrotoxic acute kidney injury in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

When NRF2 talks, who's listening?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Epigallocatechin-3-gallate augments antioxidant activities and inhibits inflammation during bleomycin-induced experimental pulmonary fibrosis through Nrf2-Keap1 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

NF-kappaB/p65 antagonizes Nrf2-ARE pathway by depriving CBP from Nrf2 and facilitating recruitment of HDAC3 to MafK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Disruption of Nrf2 Enhances the Upregulation of Nuclear Factor-kappaB Activity, Tumor Necrosis Factor-α, and Matrix Metalloproteinase-9 after Spinal Cord Injury in Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Disruption of Nrf2 enhances upregulation of nuclear factor-kappaB activity, proinflammatory cytokines, and intercellular adhesion molecule-1 in the brain after traumatic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Keap1: one stone kills three birds Nrf2, IKKβ and Bcl-2/Bcl-xL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbeta

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

15-Deoxy-Δ¹²,¹⁴-prostaglandin J₂, an electrophilic lipid mediator of anti-inflammatory and pro-resolving signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARγ, and HO-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

The triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic-acid methyl ester has potent anti-diabetic effects in diet-induced diabetic mice and Lepr(db/db) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-imidazolide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Rapid progression of diabetic nephropathy is linked to inflammation and episodes of acute renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Inflammation as a risk factor and target for therapy in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Bardoxolone methyl and kidney function in CKD with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Clinical practice. Nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

The RAAS in the pathogenesis and treatment of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Mechanisms and treatment of CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

The extinguished BEACON of bardoxolone: not a Monday morning quarterback story

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Bardoxolone Methyl, Chronic Kidney Disease, and Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Glomerular hyperfiltration and renal disease progression in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Vasopeptidase inhibition prevents nephropathy in Zucker diabetic fatty rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Antifibrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Distinct cardiac and renal effects of ETA receptor antagonist and ACE inhibitor in experimental type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Genetic or pharmacologic amplification of nrf2 signaling inhibits acute inflammatory liver injury in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

Dihydro-CDDO-trifluoroethyl amide (dh404), a novel Nrf2 activator, suppresses oxidative stress in cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT224

21 January 2018

Identifiers

DOI

10.1093/NDT/GFT224

1 reference

29 August 2017

1 reference